Correction: The dual PI3K/mTOR inhibitor dactolisib elicits anti-tumor activity
in vitro
and
in vivo
Oncotarget
.
2018 Mar 30;9(24):17255.
doi: 10.18632/oncotarget.25063.
Authors
Fei Shi
#
1
,
Jinying Zhang
#
2
,
Hongyu Liu
3
,
Liangliang Wu
3
,
Hongyu Jiang
4
,
Qiyan Wu
3
,
Tianyi Liu
3
,
Meiqing Lou
1
,
Hao Wu
5
Affiliations
1
Department of Neurosurgery, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200000, China.
2
Institute of Basic Medicine Science, Chinese PLA General Hospital, Beijing 100853, China.
3
Key Laboratory of Cancer Center, Chinese PLA General Hospital, Beijing 100853, China.
4
Department of Anesthesiology, Wuxi Third People's Hospital, Wuxi, Jiangsu 214000, China.
5
Department of Neurosurgery, Xuanwu Hospital, Capital Medical University, Beijing 100053, China.
#
Contributed equally.
PMID:
29683149
PMCID:
PMC5908321
DOI:
10.18632/oncotarget.25063
Abstract
[This corrects the article DOI: 10.18632/oncotarget.23091.].
Publication types
Published Erratum